Home

Ahmed MD Hamdy

CIK 1458506 · CMO · last filed 2026-03-23

Ahmed MD Hamdy is a CMO who has filed 23 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing, for CRIS, was dated Mar 23, 2026. Across all open-market trades the lifetime net is +$250.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $16.1K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$16.1K

Companies

3

Total Filings

23

Lifetime Open-Market Net

$250.5K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CRIS CMO 3,333 $4.83 $16.1K $0 3 2026-03-23
Vincerx Pharma, Inc. (VINC) Delisted Chief Executive Officer 85,713 $0.01 $1.1K $250.5K 12 2024-08-14
Vincerx Pharma, Inc. (VINCW) Delisted President and CEO 1,618,199 $1.61 $2.61M $0 1 2020-12-28

Recent Filings

23 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-03-23 CRIS Conv (C) +66,667 $0 EDGAR
2026-03-18 CRIS Grant (A) — $0 EDGAR
2025-05-05 CRIS Grant (A) — $0 EDGAR
2024-08-14 Vincerx Pharma, Inc. (VINC) Delisted Mixed — $0 EDGAR
2024-05-29 Vincerx Pharma, Inc. (VINC) Delisted Grant (A) — $0 EDGAR
2024-03-08 Vincerx Pharma, Inc. (VINC) Delisted Grant (A) — $0 EDGAR
2023-08-10 Vincerx Pharma, Inc. (VINC) Delisted Buy (P) +22,300 $21.2K EDGAR
2023-02-16 Vincerx Pharma, Inc. (VINC) Delisted Grant (A) — $0 EDGAR
2022-12-14 Vincerx Pharma, Inc. (VINC) Delisted Buy (P) +35,280 $30.5K EDGAR
2022-11-17 Vincerx Pharma, Inc. (VINC) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 23
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.